Neuropathic Pain News and Research RSS Feed - Neuropathic Pain News and Research

Neuropathic pain is a type of pain that is caused by damage to the nervous system following an injury or illness and affects approximately 1% of the population.
Transplant drug rapamycin may reduce nerve damage, neuropathic pain after spinal cord injury

Transplant drug rapamycin may reduce nerve damage, neuropathic pain after spinal cord injury

New research in mice indicates that a drug commonly used to suppress the immune system in recipients of organ transplants may also reduce tissue damage and neuropathic pain after spinal cord injury. The findings are published in the Journal of Orthopaedic Research. [More]
IU researchers identify suite of genes that play role in nerve sensitivity

IU researchers identify suite of genes that play role in nerve sensitivity

Indiana University researchers have that found a suite of genes in both fruit flies and humans -- including one dubbed "smoke alarm" -- plays a role in nerve sensitivity. The study could help lead to new drug targets in pain management. [More]
Drexel University researchers aim to identify new molecular mechanisms involved in chronic pain

Drexel University researchers aim to identify new molecular mechanisms involved in chronic pain

Chronic pain is one of the most prevalent, disabling and expensive public health crises in the United States. It affects more than 100 million Americans, with annual costs estimated at $635 billion, says a 2014 report from the American Pain Society. [More]
Nonopioid interventional options for chronic pain not covered by insurance in few U.S. states

Nonopioid interventional options for chronic pain not covered by insurance in few U.S. states

Recent studies have shown significant therapeutic value from the use of high-frequency - 10,000 (HF-10) spinal cord stimulation (SCS) for patients experiencing chronic back and leg pain. [More]
Maternal pregabalin exposure linked to major birth defect risk

Maternal pregabalin exposure linked to major birth defect risk

First trimester exposure to pregabalin may be associated with an increased risk of major birth defects, an observational study suggests. [More]
Taking pregabalin drug during pregnancy could lead to major birth defects

Taking pregabalin drug during pregnancy could lead to major birth defects

A drug commonly used to treat pain, epilepsy, anxiety and other brain health disorders may be associated with an increased risk of major birth defects, according to a study published in the May 18, 2016, online issue of Neurology, the medical journal of the American Academy of Neurology. [More]
Gene therapy could be potential treatment for neuropathic pain in cancer patients

Gene therapy could be potential treatment for neuropathic pain in cancer patients

A study providing new information about neuropathic pain afflicting some 90 percent of cancer patients who have had nerve damage caused by tumors, surgery, chemotherapy or radiation indicates gene therapy as a possible treatment. [More]
Scientists discover CD2AP protein that plays key role in nervous system

Scientists discover CD2AP protein that plays key role in nervous system

University of Louisville researchers have discovered that a protein previously known for its role in kidney function also plays a significant role in the nervous system. In an article featured in the April 13 issue of the Journal of Neuroscience, they show that the adaptor protein CD2AP is a key player in a type of neural growth known as collateral sprouting. [More]
Psychedelic compounds could treat patients with mental health issues

Psychedelic compounds could treat patients with mental health issues

Psychedelic compounds have had a colorful past. Although initially investigated for medical uses, they were banned after cultural and political times changed in the 1960s and 1970s. Now, the compounds are getting another chance in the mainstream, according to the cover story of Chemical & Engineering News, the weekly news magazine of the American Chemical Society. [More]
Neurofeedback decreases pain, increases quality of life in patients with neuropathic pain

Neurofeedback decreases pain, increases quality of life in patients with neuropathic pain

A new study from The University of Texas MD Anderson Cancer Center evaluating the use of neurofeedback found a decrease in the experience of chronic pain and increase quality of life in patients with neuropathic pain. [More]
Botulinum toxin A injections combat neuropathic pain

Botulinum toxin A injections combat neuropathic pain

Botulinum toxin A injections have a sustained beneficial effect in patients with neuropathic pain, shows a randomised trial. [More]
Promising therapeutic strategy for relieving neuropathic pain

Promising therapeutic strategy for relieving neuropathic pain

A specific molecule involved in maintaining pain after a nerve injury has been identified and blocked in mice by Hiroshima University researchers. These results reveal a promising therapeutic strategy for treating neuropathic pain. [More]
Drugs designed to curb Rac1 signaling pathway may help relieve inflammatory pain in sufferers

Drugs designed to curb Rac1 signaling pathway may help relieve inflammatory pain in sufferers

New research uncovers a cascade of reactions within nerve cells that relay sensations of pain associated with inflammation. The findings, which are published in the British Journal of Pharmacology, indicate that drugs designed to curb this pathway may help relieve inflammatory pain in sufferers. [More]
Noninvasive FMRI may help evaluate effectiveness of new pain medications

Noninvasive FMRI may help evaluate effectiveness of new pain medications

New research may allow new, more effective and safer pain medications to reach patients who suffer from chronic pain sooner. According to a recent study published in Anesthesiology, the official medical journal of the American Society of Anesthesiologists, using functional magnetic resonance imaging (FMRI), to measure the brain's neural response to pain, may be a viable tool for evaluating the effectiveness of new pain medications during the early stages of human drug development - providing the needed objective evidence to prevent the premature discarding of potentially beneficial therapies. [More]
Opioid medication does not improve physical function in patients with neuropathic pain

Opioid medication does not improve physical function in patients with neuropathic pain

Opioids such as morphine, codeine and Tylenol 3 can be effective for treating pain, however, a new University of Alberta study finds that patients with neuropathic pain taking opioids report no improvements in physical functioning compared to those who were not prescribed opioids. [More]
BlueWind completes patient enrolment for Overactive Bladder study to support CE Mark submission

BlueWind completes patient enrolment for Overactive Bladder study to support CE Mark submission

BlueWind Medical, developer of a wireless neuro-stimulation device to treat multiple clinical indications, such as back pain, peripheral neuropathic pain, incontinence (OAB), epilepsy, and more, announced today the completion of patient enrolment for an Overactive Bladder (OAB) study which is currently being conducted to support CE Mark submission. [More]
Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune enters into exclusive license with Atlante Biotech for new format of bispecific antibodies

Immune Pharmaceuticals Inc. a clinical-stage company developing novel therapies for the treatment of immuno-inflammatory diseases and cancer, today announced it has entered into an exclusive license with Atlante Biotech SAS, to the patents and know-how for a new format of bispecific antibodies. [More]
Circuit awarded contract to pursue optogenetic therapies for peripheral nervous system indications

Circuit awarded contract to pursue optogenetic therapies for peripheral nervous system indications

Circuit Therapeutics today announced that it has been awarded a 2.7 million dollar contract from the Defense Advanced Research Projects Agency to pursue optogenetic therapies for peripheral nervous system indications. The award, part of DARPA's Electrical Prescriptions (ElectRX) program, will enable Circuit to pursue research and development projects related to its treatment for neuropathic pain. [More]
First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

First patient enrolled in Phase 2 clinical trial of Immune's bertilimumab in Ulcerative Colitis

Immune Pharmaceuticals Inc. announced today that the first patient has been enrolled into the Phase 2 clinical trial evaluating the safety and efficacy of its first in class fully human monoclonal antibody, bertilimumab in Ulcerative Colitis (UC). [More]
Study opens new doors to research possible treatment for patients suffering from neuropathic pain

Study opens new doors to research possible treatment for patients suffering from neuropathic pain

Chronic pain results from disease or trauma to the nervous system. Damaged nerve fibres with heightened responses to normal stimuli send incorrect messages to pain centres in the brain. This phenomenon, called "peripheral and central sensitization" is one of the key mechanisms involved in the condition which touches people with diabetes, cancer, and those suffering from multiple sclerosis, among others. [More]
Advertisement
Advertisement